Managing pediatric patients with psoriasis

Susan Bard, Daniele Torchia, Lawrence A Schachner

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Childhood-onset psoriasis affects approximately one-third of the psoriatic population. Among many potential treatments of childhood psoriasis, biological agents are emerging as a valuable option in the management of this disease. In Europe, etanercept has recently been approved for children aged 8 years and over. Data from a well-designed clinical trial indicate that in children, etanercept effectively reduces psoriasis symptoms, with beneficial effects evident as early as 4 weeks after the initiation of treatment. Etanercept is well tolerated; adverse effects are typically mild to moderate in severity. Early data from other biological agents are promising.

Original languageEnglish
Pages (from-to)15-17
Number of pages3
JournalAmerican Journal of Clinical Dermatology
Volume11
Issue numberSUPPL. 1
DOIs
StatePublished - Jul 9 2010

Fingerprint

Psoriasis
Biological Factors
Pediatrics
Disease Management
Clinical Trials
Therapeutics
Population
Etanercept

ASJC Scopus subject areas

  • Dermatology

Cite this

Managing pediatric patients with psoriasis. / Bard, Susan; Torchia, Daniele; Schachner, Lawrence A.

In: American Journal of Clinical Dermatology, Vol. 11, No. SUPPL. 1, 09.07.2010, p. 15-17.

Research output: Contribution to journalArticle

Bard, Susan ; Torchia, Daniele ; Schachner, Lawrence A. / Managing pediatric patients with psoriasis. In: American Journal of Clinical Dermatology. 2010 ; Vol. 11, No. SUPPL. 1. pp. 15-17.
@article{2a5207688fea4b2cb812356b34679edb,
title = "Managing pediatric patients with psoriasis",
abstract = "Childhood-onset psoriasis affects approximately one-third of the psoriatic population. Among many potential treatments of childhood psoriasis, biological agents are emerging as a valuable option in the management of this disease. In Europe, etanercept has recently been approved for children aged 8 years and over. Data from a well-designed clinical trial indicate that in children, etanercept effectively reduces psoriasis symptoms, with beneficial effects evident as early as 4 weeks after the initiation of treatment. Etanercept is well tolerated; adverse effects are typically mild to moderate in severity. Early data from other biological agents are promising.",
author = "Susan Bard and Daniele Torchia and Schachner, {Lawrence A}",
year = "2010",
month = "7",
day = "9",
doi = "10.2165/1153415-S0-000000000-00000",
language = "English",
volume = "11",
pages = "15--17",
journal = "American Journal of Clinical Dermatology",
issn = "1175-0561",
publisher = "Adis International Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Managing pediatric patients with psoriasis

AU - Bard, Susan

AU - Torchia, Daniele

AU - Schachner, Lawrence A

PY - 2010/7/9

Y1 - 2010/7/9

N2 - Childhood-onset psoriasis affects approximately one-third of the psoriatic population. Among many potential treatments of childhood psoriasis, biological agents are emerging as a valuable option in the management of this disease. In Europe, etanercept has recently been approved for children aged 8 years and over. Data from a well-designed clinical trial indicate that in children, etanercept effectively reduces psoriasis symptoms, with beneficial effects evident as early as 4 weeks after the initiation of treatment. Etanercept is well tolerated; adverse effects are typically mild to moderate in severity. Early data from other biological agents are promising.

AB - Childhood-onset psoriasis affects approximately one-third of the psoriatic population. Among many potential treatments of childhood psoriasis, biological agents are emerging as a valuable option in the management of this disease. In Europe, etanercept has recently been approved for children aged 8 years and over. Data from a well-designed clinical trial indicate that in children, etanercept effectively reduces psoriasis symptoms, with beneficial effects evident as early as 4 weeks after the initiation of treatment. Etanercept is well tolerated; adverse effects are typically mild to moderate in severity. Early data from other biological agents are promising.

UR - http://www.scopus.com/inward/record.url?scp=77954266281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954266281&partnerID=8YFLogxK

U2 - 10.2165/1153415-S0-000000000-00000

DO - 10.2165/1153415-S0-000000000-00000

M3 - Article

VL - 11

SP - 15

EP - 17

JO - American Journal of Clinical Dermatology

JF - American Journal of Clinical Dermatology

SN - 1175-0561

IS - SUPPL. 1

ER -